Glaxosmithkline Pharmaceuticals Ltd (GLAXO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 793005,
    "name": "Glaxosmi. Pharma",
    "stock_name": "Glaxosmi. Pharma",
    "full_name": "Glaxosmithkline Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/glaxosmi-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,423.65",
    "chg": -2.75,
    "chgp": "-0.11%",
    "dir": -1,
    "prev_price": "2,426.40",
    "mcapval": "41,675.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": 500660,
    "symbol": "GLAXO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE159A01016",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "93.83 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/glaxosmi-pharma-793005-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Glaxosmi. Pharma’s Evaluation Revised Amidst Challenging Market Conditions",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmi-pharma-downgraded-to-sell-by-marketsmojo-amid-valuation-concerns-3731005",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GlaxosmiPharma_mojoScore_3731005.png",
        "date": "2025-11-26 09:46:20",
        "description": "Glaxosmi. Pharma has undergone a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment and stock performance within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Are Glaxosmi. Pharma latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-glaxosmi-pharma-latest-results-good-or-bad-3680521",
        "imagepath": "",
        "date": "2025-11-07 19:22:53",
        "description": "GlaxoSmithKline Pharmaceuticals reported its Q2 FY26 results, highlighting a complex operational landscape. The company achieved a net profit of ₹257.49 crores, reflecting a quarter-on-quarter growth of 25.60%, while year-on-year growth was modest at 1.98%. This indicates a strong performance in profitability, driven primarily by improved operational efficiencies.\n\nHowever, revenue for the same quarter was ₹979.94 crores, which represents a decline of 3.05% year-on-year, marking the second consecutive quarter of negative growth in this metric. Despite a significant quarter-on-quarter increase of 21.71%, the overall trend raises concerns about the sustainability of revenue generation in a competitive market.\n\nOperationally, the company demonstrated notable efficiency with an operating margin of 34.26%, the highest in eight quarters, attributed to better product mix management and effective cost control measu..."
      },
      {
        "title": "How has been the historical performance of Glaxosmi. Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-glaxosmi-pharma-3677204",
        "imagepath": "",
        "date": "2025-11-06 22:57:25",
        "description": "Answer:\nThe historical performance of Glaxosmi. Pharma shows a consistent growth trend in net sales and profitability over the years leading up to March 2025.\n\nBreakdown:\nGlaxosmi. Pharma's net sales have increased from 3,128.12 crore in March 2019 to 3,749.21 crore in March 2025, reflecting a steady upward trajectory. The total operating income followed a similar pattern, rising from 3,128.12 crore in March 2019 to 3,749.21 crore in March 2025. The company's operating profit (PBDIT) has also seen significant growth, climbing from 703.11 crore in March 2019 to 1,323.29 crore in March 2025, with an operating profit margin that improved from 19.21% to 31.4% over the same period. Profit before tax surged from 682.66 crore in March 2019 to 1,259.88 crore in March 2025, while profit after tax reached 927.58 crore in March 2025, up from 445.39 crore in March 2019. The earnings per share (EPS) increased notably fr..."
      },
      {
        "title": "Why is Glaxosmi. Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-glaxosmi-pharma-fallingrising-3676888",
        "imagepath": "",
        "date": "2025-11-06 22:36:27",
        "description": "As of 06-Nov, Glaxosmithkline Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 2,599.75, reflecting a decrease of 61.75 points or 2.32%. The stock has underperformed its sector by 1.55% today and has been on a downward trend for the last two days, accumulating a total loss of 3.19% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Despite a high management efficiency with a return on equity (ROE) of 42.32% and a low debt-to-equity ratio, the company faces challenges such as poor long-term growth, with net sales growing at an annual rate of only 3.92% over the last five years, and a high valuation compared to its peers, which may be contributing to the stock's recent decline.\n\nIn the broader market context, Glaxosmithkline's short-term performance has been relatively better th..."
      },
      {
        "title": "GlaxoSmithKline Pharmaceuticals Q2 FY26: Premium Valuation Under Pressure as Growth Stalls",
        "link": "https://www.marketsmojo.com/news/result-analysis/glaxosmithkline-pharmaceuticals-q2-fy26-premium-valuation-under-pressure-as-growth-stalls-3677787",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/Glaxosmithkline_quaterlyResult_3677787.png",
        "date": "2025-11-06 19:33:12",
        "description": "GlaxoSmithKline Pharmaceuticals Ltd. reported a modest net profit of ₹257.49 crores for Q2 FY26, marking a 25.60% quarter-on-quarter increase but a mere 1.98% year-on-year growth. The pharmaceutical major, with a market capitalisation of ₹44,633 crores, continues to grapple with anaemic top-line expansion whilst maintaining its premium valuation at 47 times trailing earnings. The stock has declined 2.32% following the results announcement, trading at ₹2,599.75 and reflecting investor concerns about the sustainability of its lofty multiples in the face of stagnating revenue growth."
      }
    ],
    "total": 5143,
    "sid": "793005",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/glaxosmithkline-pharmaceuticals-793005"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "08-Jan-2026",
      "details": "As per Attachment",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Un-Audited Financial Results For The Third Quarter & Nine Months Ended 31St December 2025.",
      "datetime": "06-Jan-2026",
      "details": "Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 inter alia to consider and approve take on record the Un-audited financial results for the third quarter & nine months ended 31st December 2025.",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 30",
      "datetime": "01-Jan-2026",
      "details": "As per attachment",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Glaxosmithkline Pharmaceuticals Ltd has declared <strong>420%</strong> dividend, ex-date: 30 May 25",
          "dt": "2025-05-30",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Glaxosmithkline Pharmaceuticals Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 11 Sep 18",
          "dt": "2018-09-11",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Glaxosmi. Pharma’s Evaluation Revised Amidst Challenging Market Conditions

2025-11-26 09:46:20

Glaxosmi. Pharma has undergone a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment and stock performance within the Pharmaceuticals & Biotechnology sector.

Are Glaxosmi. Pharma latest results good or bad?

2025-11-07 19:22:53

GlaxoSmithKline Pharmaceuticals reported its Q2 FY26 results, highlighting a complex operational landscape. The company achieved a net profit of ₹257.49 crores, reflecting a quarter-on-quarter growth of 25.60%, while year-on-year growth was modest at 1.98%. This indicates a strong performance in profitability, driven primarily by improved operational efficiencies. However, revenue for the same quarter was ₹979.94 crores, which represents a decline of 3.05% year-on-year, marking the second consecutive quarter of negative growth in this metric. Despite a significant quarter-on-quarter increase of 21.71%, the overall trend raises concerns about the sustainability of revenue generation in a competitive market. Operationally, the company demonstrated notable efficiency with an operating margin of 34.26%, the highest in eight quarters, attributed to better product mix management and effective cost control measu...

How has been the historical performance of Glaxosmi. Pharma?

2025-11-06 22:57:25

Answer: The historical performance of Glaxosmi. Pharma shows a consistent growth trend in net sales and profitability over the years leading up to March 2025. Breakdown: Glaxosmi. Pharma's net sales have increased from 3,128.12 crore in March 2019 to 3,749.21 crore in March 2025, reflecting a steady upward trajectory. The total operating income followed a similar pattern, rising from 3,128.12 crore in March 2019 to 3,749.21 crore in March 2025. The company's operating profit (PBDIT) has also seen significant growth, climbing from 703.11 crore in March 2019 to 1,323.29 crore in March 2025, with an operating profit margin that improved from 19.21% to 31.4% over the same period. Profit before tax surged from 682.66 crore in March 2019 to 1,259.88 crore in March 2025, while profit after tax reached 927.58 crore in March 2025, up from 445.39 crore in March 2019. The earnings per share (EPS) increased notably fr...

Why is Glaxosmi. Pharma falling/rising?

2025-11-06 22:36:27

As of 06-Nov, Glaxosmithkline Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 2,599.75, reflecting a decrease of 61.75 points or 2.32%. The stock has underperformed its sector by 1.55% today and has been on a downward trend for the last two days, accumulating a total loss of 3.19% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Despite a high management efficiency with a return on equity (ROE) of 42.32% and a low debt-to-equity ratio, the company faces challenges such as poor long-term growth, with net sales growing at an annual rate of only 3.92% over the last five years, and a high valuation compared to its peers, which may be contributing to the stock's recent decline. In the broader market context, Glaxosmithkline's short-term performance has been relatively better th...

GlaxoSmithKline Pharmaceuticals Q2 FY26: Premium Valuation Under Pressure as Growth Stalls

2025-11-06 19:33:12

GlaxoSmithKline Pharmaceuticals Ltd. reported a modest net profit of ₹257.49 crores for Q2 FY26, marking a 25.60% quarter-on-quarter increase but a mere 1.98% year-on-year growth. The pharmaceutical major, with a market capitalisation of ₹44,633 crores, continues to grapple with anaemic top-line expansion whilst maintaining its premium valuation at 47 times trailing earnings. The stock has declined 2.32% following the results announcement, trading at ₹2,599.75 and reflecting investor concerns about the sustainability of its lofty multiples in the face of stagnating revenue growth.

View All News